A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, PEHRG214, in HIV-1-infected individuals

HIV Clinical Trials

Volumn 5, Issue 2, 2004, Pages 91-98

  Pett, Sarah L ^a,b   Williams, Lisa A ^c,d   Day, Richard O ^e   Lloyd, Andrew R ^e,f   Carr, Andrew D ^a   Clezy, Kathleen R ^b,f   Emery, Sean ^b   Kaplan, Errol ^g   McPhee, Dale A ^h   McLachlan, Andrew J ⁱ   Gelder, Frank B ^d   Lewin, Sharon R ^j   Liauw, Winston ^e   Williams, Kenneth M ^e  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d Virionyx Corporation Ltd   (New Zealand)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f PRINCE OF WALES HOSPITAL   (Australia)

^g Probe Pharmaceuticals   (Australia)

^h BURNET INSTITUTE   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Caprine antibody; Neutralizing; Passive immunotherapy

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NORLEUCINE; POLYCLONAL ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; OPEN STUDY; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECIPIENT; SERUM SICKNESS; SINGLE DRUG DOSE; T LYMPHOCYTE; URTICARIA; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; AREA UNDER CURVE; GOATS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; MALE; PILOT PROJECTS;

EID: 2542536738     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/1FLN-8KFC-5HEQ-K19J     Document Type: Article

References (36)

1. UNAIDS/WHO global AIDS statistics. AIDS Care. 2003;15(1):144.
2. Schooley RT. Longer term immunologic effects and side effects of successful antiretroviral therapy. Clin Infect Dis. 1999;29(1):12-18.
3. Forum for Collaborative HIV Research, George Washington University Medical Center. The challenges of clinical trial design in assessing the effects of anti-HIV therapy in heavily pre-treated patients, May 1999. Available at http://www.hivforum.org.
4. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-1983.
5. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
6. Soriano V, Garcia-Samaniego J, Valencia E, et al. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol. 1999;15:1-4.
7. Martin-Carbonero L, Soriano V, Valencia ME, et al. Impact of chronic viral hepatitis on hospital admissions and mortality in HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17:1467-1471.
8. Monga H, Rodriguez-Barradas M, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with HIV infection. Clin Infect Dis. 2001;33:240-247.
9. Evaluation of Subcutaneous Proleukin® in a Randomised International Trial (ESPRIT). Available at: http://www.esprit-il2.org.
10. Peters BS. The basis for HIV immunotherapeutic vaccines. Vaccine. 2002;20:688-705.
11. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998;393:705-711.
12. Pilgrim AK, Panateleo G, Cohen OJ, et al. Neutralisng antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis. 1997;176:924-932.
13. Vittecoq D, Mattlinger B, Barre-Sinoussi F, et al. Passive immunotherapy in AIDS: a randomised trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis. 1992;165:364-368.
14. Karpas A, Hewlett IK, Hill F. Polymerase chain reaction evidence for human immunodeficiency virus neutralisation by passive immunisation in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci USA. 1990;87:7613-7617.
15. Blick G, Scott WF, Crook SW, et al. Passive immunotherapy in advanced HIV infection and therapeutic plasmapharesis in asymptomatic HIV-positive individuals: a four year clinical experience. Biotherapy. 1998;11:7-14.
16. Vittecoq D, Chevret S, Morand-Joubert L. A double-blind randomised study based on transfusions of plasma rich in anti-HIV-1 antibodies vs. transfusion of seronegative plasma. Proc Natl Acad Sci USA. 1995;92:1195-1199.
17. Poignard PL, Klasse PJ, Sattentau QJ. Antibody neutralisation of HIV-1. Immunology Today. 1993;342:239-246.
18. Osther K, Wiik A, Black F, et al. PASS HIV-treatment of patients with HIV-1 infection. A preliminary report of a phase 1 trial of hyperimmune porcine immunoglobulin to HIV-1. AIDS. 1992;6:1457-1464.
19. Armbruster C, Stiegler GM, Vcelar BA, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS. 2002;16:227-233.
20. Stiegler G, Armbruster C, Vcelar B, et al. Antiviral activity of the neutralising antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase 1 evaluation. AIDS. 2002;16:2019-2025.
21. Mascola JR. Passive transfer studies to elucidate the role of antibody-medicated protection against HIV-1. Vaccine. 2002;20:1922-1925.
22. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Post-natal pre- and postexposure passive immunisation strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol. 2002;31:109-119.
23. Xu W, Hofmann-Lehmann R, McClure HM, et al. Passive immunization with human neutralising monoclonal antibodies: correlates of protective immunity against HIV. Vaccine. 2002;20:1956-1960.
24. PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody. Manuscript in preparation.
25. DAIDS/CPCRA toxicity table for grading adverse experiences. National Institutes of Allergy and Infectious Diseases, National Institutes of Health, January 1997. Available at http://www.niaid.nih.gov/daids.
26. Lewin SR, Vesanen M, Kostrikis L, et al. The use of realtime PCR and molecular beacons to detect virus replication in HIV-1 infected individuals on prolonged effective antiretroviral therapy. J Virol. 1999;73:6099-6103
27. Pierson T, Hoffman TL, Blankson J, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol. 2000;74:7824-7833.
28. Rowland M, Tozer TM. Clinical Pharmacokinetics, Concepts and Application, 3rd ed. London: Lea & Febiger; 1995.
29. PEHRG214, in patients infected with human immunodeficiency virus: a phase I study. JID. 2003;187(3):500-503.
30. Heller HM. Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection. Clin Derm. 2000;18:485-489.
31. Bielory L, Gascon P, Lawley TJ, et al. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine. 1988;67(1):40-57.
32. Tichelli A, Passweg J, Nissen C, et al. repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. B J Haem. 1998;100(2):393-400.
33. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated myelodysplastic syndromes. Ann Intern Med. 2002;137:156-163.
34. Huralt de Ligny B, Lebranchu Y. The use of thymoglobuline induction in renal transplantation: a pharmacovigilance study. Trans Proc. 2000;32:351-352.
35. Prin Mathieu C, Renoult E, Kennel de March A, et al. Serum anti-rabbit and anti-horse IgG, IgA, and IgM in kidney transplant recipients. Nephrol Dial Transplant. 1997;12:2133-2139.
36. Yeni PG, Hammer SM, Carpenter CJ, et al. Antiretroviral treatment for adult HIV infection in 2002, updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288(2):222-234.